Search Results for "Merck Ness"
Original Source: Kadimastem
Kadimastem (www.kadimastem.com) is a biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell-based products. At Kadimastem, the pluripotent stem cell technology is used to produce specialized human cells and tissues for two major types of medical applications: 1) Drug-screening platforms using human functional cells and tissues as in vitro assays for discovering novel therapeutic drugs for neurol...
Matching Channels
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the...
Matching News
Ness Technologies Joins Pan-European CATO Project as Project Coordinator
To: TECHNOLOGY EDITORSTEL AVIV, Israel, June 26, 2012 /PRNewswire/ --Ness Technologies, a global provider of information technologysolutions and services, today announced that it has joined, as projec...
UNMCC researcher to investigate possible mechanism for cancer tumor development
Most of us think of DNA mutations as the culprits that cause cancer. Scott Ness, PhD, University of New Mexico Professor of Molecular Genetics and Microbiology and Associate Director at the UNM Cancer...
Mof protein preserves the ‘stem-ness’ of stem cells
University of Michigan Medical School researcher Yali Dou, Ph.D. and her team show the crucial role of a protein called Mof in preserving the ‘stem-ness’ of stem cells, and priming them to become...
Return to top 50 pharma list Summary Website: Merck & Co Headquarters: Whitehouse Station, NJ, USA Ticker: MRK (NYSE) SEC: Merck & Co Recent deal news: Merck & Co deal news at Current Part...
Study researches genetic messenger rather than gene
(University of New Mexico Cancer Center) Currently, most genetic cancer research focuses on DNA abnormalities. Dr. Scott Ness' work, funded by a recent Provocative Questions Grant award, will instead...
Calypso Biotech debuts to develop Merck Serono's IBD R&D
The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched Calypso Biotech to develop Merck Serono's preclinical R&D portfolio for gastrointestinal immunological disorders. The newco will conti...
Merck Serono to finance the launch of the EspeRare Foundation
Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Foundation, a nonprofit organization set up by three Merck Serono employees, in the framework of the M...
Did you know that Merck KGaA is the oldest pharmaceutical company in the world? Read our latest ‘a history of’ article to find out more; plus we bust the myths between Merck KGaA and Merck &...
Matching PubMed Articles
Expert Commentary-Unusual Headache Syndromes.
Three-drug combination regimen in pancreatic cancer treatment: are we there yet?
